HC Wainwright Forecasts Lower Earnings for Niagen Bioscience

Key Points

• HC Wainwright cut its FY2026 EPS forecast for Niagen Bioscience to $0.14 from $0.28, below the current consensus estimate of $0.21; it also projects $0.14 EPS for FY2027.
• Niagen reported quarterly EPS of $0.01, matching expectations, while revenue of $29.78 million slightly missed the $29.95 million analyst estimate. The company posted a 12.39% net margin and 17.95% return on equity.
• Despite the lower earnings outlook, HC Wainwright maintained its Buy rating. Analysts have an overall “Buy” consensus and an average price target of $10.33, compared with the stock’s recent $3.04 price.

Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) - Investment analysts at HC Wainwright reduced their FY2026 earnings estimates for Niagen Bioscience in a note issued to investors on Wednesday, August 5th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.14 per share for the year, down from their prior forecast of $0.28. HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Niagen Bioscience's current full-year earnings is $0.21 per share. HC Wainwright also issued estimates for Niagen Bioscience's Q4 2026 earnings at $0.02 EPS and FY2027 earnings at $0.14 EPS.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01. The company had revenue of $29.78 million during the quarter, compared to analyst estimates of $29.95 million. Niagen Bioscience had a net margin of 12.39% and a return on equity of 17.95%.

A number of other equities research analysts have also commented on NAGE. Wall Street Zen lowered Niagen Bioscience from a "buy" rating to a "hold" rating in a research report on Saturday, April 25th. Weiss Ratings reiterated a "hold (c)" rating on shares of Niagen Bioscience in a research report on Friday, July 17th. Freedom Capital raised Niagen Bioscience to a "strong-buy" rating in a research note on Monday, July 6th. Roth Capital restated a "buy" rating on shares of Niagen Bioscience in a report on Wednesday. Finally, Canaccord Genuity Group lowered their target price on Niagen Bioscience from $13.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, May 5th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $10.33.

Niagen Bioscience Trading Up 2.7%

NASDAQ:NAGE opened at $3.04 on Friday. The stock has a market capitalization of $242.11 million, a P/E ratio of 16.89 and a beta of 2.09. Niagen Bioscience has a 1 year low of $2.87 and a 1 year high of $11.29. The firm has a 50 day moving average of $3.40 and a 200-day moving average of $4.32.

Institutional Investors Weigh In On Niagen Bioscience

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. bought a new position in Niagen Bioscience in the third quarter valued at about $37,522,000. SteelPeak Wealth LLC bought a new stake in Niagen Bioscience during the 1st quarter worth about $14,875,000. Arrowstreet Capital Limited Partnership bought a new stake in Niagen Bioscience during the 3rd quarter worth about $13,405,000. UBS Group AG acquired a new position in Niagen Bioscience during the 3rd quarter valued at about $11,160,000. Finally, Qube Research & Technologies Ltd acquired a new position in Niagen Bioscience during the 3rd quarter valued at about $8,175,000. 15.41% of the stock is owned by institutional investors and hedge funds.

Niagen Bioscience News Roundup

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Expanded Walmart distribution: Niagen launched its Tru Niagen healthy-aging supplement on Walmart.com, increasing access through a major e-commerce platform and diversifying its online sales channels. The move could support consumer reach, revenue growth and brand visibility. Niagen Bioscience Launches Tru Niagen on Walmart.com
• Positive Sentiment: Potentially higher fair value: Coverage discussing a new aging study argues that Niagen’s NAD+ and healthy-aging opportunity may justify a higher valuation, offering a bullish long-term view of the company’s research and commercial prospects. Niagen Bioscience On New Aging Study And the Case for a Higher Fair Value
• Neutral Sentiment: Buy rating retained: Despite lowering its estimates, HC Wainwright maintained a “Buy” rating on NAGE, indicating the analyst still sees longer-term upside.
• Negative Sentiment: Sharp earnings-estimate reductions: HC Wainwright cut its Q3 2026 EPS forecast to $0.02 from $0.08 and reduced its Q4 2026 forecast to $0.02 from $0.10. It also lowered its FY2026 estimate to $0.14 from $0.28.
• Negative Sentiment: Weaker 2027 outlook: The firm reduced FY2027 EPS expectations to $0.14 from $0.36, while cutting quarterly 2027 forecasts, including Q1 to $0.03 from $0.06, Q2 to $0.03 from $0.08, Q3 to $0.04 from $0.10 and Q4 to $0.05 from $0.12. These revisions suggest more cautious assumptions about near-term profitability and could weigh on valuation.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source